As monotherapy with cblb-deficient polyclonal CD8+ T cells did not provoke any benefit in neither B16.ova melanoma nor EG.7 lymphoma injected immunocompetent mice in our hands, we established a combination therapy of ACT of cblb-deficient CD8+ T cells and DC vaccination, resulting in delayed tumor outgrowth and significantly prolonged survival rates when DC vaccination was combined with ACT of cblb-deficient instead of wt CD8+ T cells (74). The gene discussed is CD8A; the disease is lymphoma.